Summary
For Year 2026-27, Bliss GVS Pharma reports the following shareholding: Total Promoters at 35.36%, Mutual Fund at 0%, Insurance at 4.33%, Foreign Institutional Investors at 10.45%, Domestic Institutional Investors at 0.71%, and Retail at 49.15%. This breakdown provides a quick snapshot of ownership distribution for Bliss GVS Pharma in 2026-27.
Bliss GVS Pharma FAQs
As of 04-2026, the promoter shareholding in Bliss GVS Pharma stands at 35.36% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Bliss GVS Pharma is 10.45% and 0.71% respectively.
The retail shareholding of the Bliss GVS Pharma is 49.15%.
Changes in shareholding patterns of Bliss GVS Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Bliss GVS Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
